MedTrace Logo

QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.

NCT05287139 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2022-03-18

No results posted yet for this study

Summary

Assess the quality of life in patients with hormone receptor positive, human epidermal growth factor receptor-type 2 negative metastatic breast cancer treated in first line (patients with new metastasis or recurrence during adjuvant endocrine therapy): comparison between public and private institutions. The hypothesis to be evaluated is that patients treated in private institutions have a better quality of life when compared to patients treated in public institutions.

Conditions

  • Quality of Life
  • Breast Neoplasm Female

Interventions

OTHER

Quality of Life

Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires

Sponsors & Collaborators

  • Beneficência Portuguesa de São Paulo

    lead OTHER

Principal Investigators

  • Débora G Jardim, MD · Beneficência Portuguesa de São Paulo

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2022-07-30
Completion
2022-07-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05287139 on ClinicalTrials.gov